SARcode Corporation has named Todd Creech as chief financial officer (CFO) and vice president of business development. Creech has been fulfilling both positions as a consultant to SARcode since November 2010.
Creech has over 11 years of executive experience in finance and business development in the pharmaceutical and biotech industries, predominantly with early-stage companies. Most recently, he served as CFO at Sirion Therapeutics, where he was responsible for financing strategy, accounting, capital structure, treasury, legal, and information technology. Sirion raised over US$100m in debt and equity to support the license and development of six clinical programmes, two of which were approved by the Food and Drug Administration (FDA) and commercialised. In the first half of 2010, Creech led the sale of Sirion’s assets to Alcon and Bausch and Lomb.
Prior to his tenure at Sirion, Creech worked with NovaQuest, the investment group within Quintiles, structuring, placing and managing capital investments into emerging biotech and specialty pharmaceutical companies. Additionally, his past experience includes co-founding Centice, an optical sensor spin-out of Duke University, and over 10 years of consulting experience with start-up and Fortune 100 pharmaceutical, biotech, and high-tech companies while at SRI International and Andersen Consulting. Creech holds bachelors degrees in finance and accounting from Miami University of Ohio and a MBA from Duke University’s Fuqua School of Business.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.